Biotest announces the new Renate & Hans Schleussner Award for scientific research
- Award's aim is promotion of innovative research in the field of therapies with (hyper-) immunoglobulins
- In memory of the Schleussner family who founded Biotest, the new research award will be named the Renate & Hans Schleussner Award
- € 50,000 will be awarded for a preclinical or clinical project
Dreieich, 15 September 2021. Biotest announced today that a new scientific award, the Renate & Hans Schleussner Award, which will be available and open for application from now on. The daughter from Renate & Hans, Cathrin Schleussner was a member of the Supervisory Board of "Biotest AG" since 2001 and held the position of Deputy Chairman from 2004 until the takeover by the Chinese "Creat Group" in 2018.
Immunoglobulins are a major component of the immune system. They are a potent natural tool to counteract viral and bacterial infections.
Scientists or clinicians with innovative ideas relevant to the prevention or treatment of viral infections with (hyper-) immunoglobulins are invited to submit their application. Projects should be related to pathology or management of the disease. Applicants must submit an original research contribution to basic or clinical research. Applications are encouraged from both individuals and teams conducting research at hospitals, universities or independent institutions.
Submissions will be evaluated by Biotest and an independent expert jury consisting of the following members: Prof. Martina Sester (Germany), Prof. Emanuele Cozzi (Italy), Prof. Stephen Jolles (U.K.), Prof. Srini Kaveri (France).
Deadline for the submission of a first project concept is January 31st, 2022. Selected awardees will be invited to prepare a full project proposal. Details on how to apply for the award can be found at:
Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive care medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumin based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. Biotest has more than 1,900 employees worldwide. The ordinary and preference shares of Biotest AG are listed in the Prime Standard on the German stock exchange.
Dr Monika Buttkereit
Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com
Ordinary shares: securities' ID No. 522720; ISIN DE0005227201
Preference shares: securities' ID No. 522723; ISIN DE0005227235
Listing: Frankfurt (Prime Standard)
Open Market: Berlin, Düsseldorf, Hamburg/ Hanover, Munich, Stuttgart, Tradegate
This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.
15.09.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de